A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

NCT05376150 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: XEN1101 10 mg
DRUG: XEN1101 20 mg
DRUG: Placebo

Sponsor

Xenon Pharmaceuticals Inc.